TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27856240

Group type: EXPERIMENTAL
Intervention: 1-step procedure
Number of subjects: 1878

Group type: COMPARATOR
Intervention: 2-step procedure
Number of subjects: 1878
Study: 26554457

Group type: EXPERIMENTAL
Intervention: Power training (high-velocity, high-intensity progressive resistance training) at 80%1RM, 3 days per week for 12 months
Number of subjects: 103

Group type: COMPARATOR
Intervention: Sham exercise control group (non-progressive, low-intensity training)
Number of subjects: 103
Study: 23646467

Group type: EXPERIMENTAL
Intervention: Yang deficiency group
Number of subjects: 145

Group type: COMPARATOR
Intervention: Yin deficiency group
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 145
Study: 21212932

Group type: EXPERIMENTAL
Intervention: Lowest tertile of serum potassium (2.8-3.9 mmol/l)
Number of subjects: 4409

Group type: EXPERIMENTAL
Intervention: Baseline serum potassium level
Number of subjects: 4409
Study: 19302913

Group type: EXPERIMENTAL
Intervention: Generic formulation of topiramate 100 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Branded formulation of topiramate 100 mg
Number of subjects: 28
Study: 17761627

Group type: EXPERIMENTAL
Intervention: Two-hour training session in communication skills and tobacco cessation counseling
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 104
Study: 15187074

Group type: EXPERIMENTAL
Intervention: SPPARO (System Providing Patients Access to Records Online)
Number of subjects: 394
Study: 11584936

Group type: EXPERIMENTAL
Intervention: Phlogenzym (2-3 tablets, bid)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Diclofenac sodium 50 mg bid
Number of subjects: 50
Study: 9689205

Group type: EXPERIMENTAL
Intervention: Alora (0.05 mg/day applied for 3‐4 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Climara (0.05 mg/day applied for 7 days)
Number of subjects: 27
Study: 8270987

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (IFN) 50 x 10(6) IU
Number of subjects: 287

Group type: COMPARATOR
Intervention: Mitomycin (MIT‐C) 40 mg
Number of subjects: 287
Study: 2504944

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study: 359492

Group type: EXPERIMENTAL
Intervention: 8 mg oxyfedrine i.v. in 10 patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo in 5 patients
Number of subjects: 15
Study: 31690179

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy
Number of subjects: 51769

Group type: EXPERIMENTAL
Intervention: Colonoscopy after positive flexible sigmoidoscopy
Number of subjects: 51769

Group type: COMPARATOR
Intervention: Faecal occult blood test (control)
Number of subjects: 51769
Study: 28711472

Group type: EXPERIMENTAL
Intervention: Ketamine (NMDAR antagonist)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nicotine (nAChR agonist)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ketamine + Nicotine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ketamine (compared to schizophrenia patients)
Number of subjects: 30
Study: 26819186

Group type: EXPERIMENTAL
Intervention: Minimally invasive treatment (VAAPS)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Conventional treatment (Bascom cleft lift procedure)
Number of subjects: 145
Study: 24836780

Group type: EXPERIMENTAL
Intervention: Green tea gargling (3 times a day with bottled green tea)
Number of subjects: 757

Group type: COMPARATOR
Intervention: Water gargling (3 times a day with tap water)
Number of subjects: 757
Study: 22934446

Group type: EXPERIMENTAL
Intervention: Generic pioglitazone (15 mg once daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Original pioglitazone (15 mg once daily)
Number of subjects: 60
Study: 20509069

Group type: EXPERIMENTAL
Intervention: Virtual reality hypnosis (VRH)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Adjunctive VR without hypnosis
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 21
Study: 18824708

Group type: EXPERIMENTAL
Intervention: 200 mg sorafenib twice per day
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: 400 mg sorafenib twice per day
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 15962376

Group type: EXPERIMENTAL
Intervention: 1‐wk regimen consisting of ranitidine bismuth citrate 400 mg b.i.d. with clarithromycin 500 mg b.i.d.
Number of subjects: 120

Group type: COMPARATOR
Intervention: 2‐wk regimen consisting of ranitidine bismuth citrate 400 mg b.i.d. with clarithromycin 500 mg b.i.d.
Number of subjects: 120
Study: 11823757

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg for 7 days, followed by 400 mg for 21 days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo (28 days)
Number of subjects: 41
Study: 10383006

Group type: EXPERIMENTAL
Intervention: Counselling on protein restriction
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual dietary advice
Number of subjects: 121
Study: 8645625

Group type: EXPERIMENTAL
Intervention: Droloxifene 40 mg o.d. (group 1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Droloxifene 100 mg o.d. (group 2)
Number of subjects: 13
Study: 1757907

Group type: EXPERIMENTAL
Intervention: Intravenous mannitol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Oral sodium taurocholate
Number of subjects: 20
Study: 6139318

Group type: EXPERIMENTAL
Intervention: Pindolol, 5 mg the evening before and on the morning, an hour prior to surgery
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 30975187

Group type: EXPERIMENTAL
Intervention: Nebulized morphine titration (NMT) for 5-25 min with IV placebo (physiologic serum)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Intravenous morphine titration (IVMT) plus nebulized placebo (physiologic serum)
Number of subjects: 850
Study: 29645086

Group type: EXPERIMENTAL
Intervention: Erlotinib plus pazopanib (erlotinib 150 mg daily, pazopanib 600 mg daily)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Erlotinib plus placebo (erlotinib 150 mg daily)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Erlotinib plus pazopanib
Number of subjects: 192
Study: 26760383

Group type: EXPERIMENTAL
Intervention: Reiki therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non-Reiki (control)
Number of subjects: 43
Study: 24337078

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 22503396

Group type: EXPERIMENTAL
Intervention: Total laparoscopic hysterectomy
Number of subjects: 753

Group type: COMPARATOR
Intervention: Total abdominal hysterectomy
Number of subjects: 753
Study: 20687361

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Perfusion CT (pCT) diagnostics
Number of subjects: 377
Study: 18551086

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day for 15 days
Number of subjects: 83
Study: 16079686

Group type: EXPERIMENTAL
Intervention: Showering the surgical site with soap and water and rinsing with normal saline
Number of subjects: 1810

Group type: COMPARATOR
Intervention: Traditional method of preoperative shower and scrub with chlorhexidine or Betadine
Number of subjects: 1810
Study: 12401597

Group type: EXPERIMENTAL
Intervention: 0.8 mL/kg of 0.25% bupivacaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1.0 mL/kg of 0.2% bupivacaine
Number of subjects: 50
Study: 10444538

Group type: EXPERIMENTAL
Intervention: High-fat preload (1 MJ)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Simple carbohydrate (CHO) preload (1 MJ)
Number of subjects: 10
Study: 8632199

Group type: EXPERIMENTAL
Intervention: Carkhuff model of communication skills training (20 hours)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 24
Study: 2284217

Group type: EXPERIMENTAL
Intervention: Lornoxicam (4 mg dose, administered as an aqueous solution, orally and intravenously)
Number of subjects: 0
Study: 7349619

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 9
Study: 31094635

Group type: EXPERIMENTAL
Intervention: Sealants with adhesive layer (light-cured separately)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sealants with uncured adhesive layer
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sealants without adhesive layer
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Ultraseal XT sealants with adhesive layer
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Sealants with adhesive layer (light cured together with sealant)
Number of subjects: 72
Study: 28068794

Group type: EXPERIMENTAL
Intervention: Caregiver strain (CSI)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Anxiety (HADS)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Depression (HADS)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Quality of life (SF‐36, EuroQol‐VAS)
Number of subjects: 195
Study: 26215551

Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Corticosteroid Injection (CSI)
Number of subjects: 116
Study: 23486303

Group type: EXPERIMENTAL
Intervention: High-frequency transcutaneous electrical nerve stimulation (TENS) applied on bilateral tender points of trapezium and supraspinatus
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-frequency transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 28
Study: 21941089

Group type: EXPERIMENTAL
Intervention: Heberbiovac-HB
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Euvax-B
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Hepavax-Gene
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Engerix-B
Number of subjects: 400
Study: 19391153

Group type: EXPERIMENTAL
Intervention: Therapist flexibility in cognitive-behavioral therapy
Number of subjects: 63
Study: 20463410

Group type: EXPERIMENTAL
Intervention: saxagliptin (2.5‐100 mg/d)
Number of subjects: 4607

Group type: COMPARATOR
Intervention: comparator (placebo, metformin, uptitrated glyburide)
Number of subjects: 4607
Study: 16143229

Group type: EXPERIMENTAL
Intervention: Venlafaxine XR 37.5 mg/day
Number of subjects: 40
Study: 12396765

Group type: EXPERIMENTAL
Intervention: Individual counselling or therapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Group therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 27
Study: 10199763

Group type: EXPERIMENTAL
Intervention: GnRHa plus spironolactone (100 mg, orally, once daily)
Number of subjects: 41

Group type: COMPARATOR
Intervention: GnRHa alone
Number of subjects: 41

Group type: COMPARATOR
Intervention: GnRHa plus flutamide (250 mg, once daily)
Number of subjects: 41
Study: 7766325

Group type: EXPERIMENTAL
Intervention: Early excision and grafting (n = 19)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Delayed excision and grafting (n = 21)
Number of subjects: 40
Study: 2121060

Group type: EXPERIMENTAL
Intervention: Original 'Lifeway' device
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Modified 'Lifeway' device with additional side-holes in GPT
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Modified 'Lifeway' device
Number of subjects: 54

Group type: COMPARATOR
Intervention: Combination of anaesthesia mask and pharyngeal airway
Number of subjects: 54
Study: 530571

Group type: EXPERIMENTAL
Intervention: Corticosteroid ester of prednisolone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Corticosteroid ester of dexamethasone
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment (all four corticosteroids)
Number of subjects: 54
Study: 29531101

Group type: EXPERIMENTAL
Intervention: Group-based behavioral activation with mindfulness (BAM), provided with eight 2-hour weekly sessions.
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Group-based behavioral activation with mindfulness (BAM)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 231
Study: 25854875

Group type: EXPERIMENTAL
Intervention: SSRIs treatment (6-week duration)
Number of subjects: 290
Study: 24504810

Group type: EXPERIMENTAL
Intervention: Abatacept (standard weight-tiered dose, approximating 10 mg/kg)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Abatacept (30 mg/kg for 3 months, then standard weight-tiered dose)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study: 22433961

Group type: EXPERIMENTAL
Intervention: quadrivalent HPV vaccine
Number of subjects: 600

Group type: COMPARATOR
Intervention: adjuvant‐containing placebo
Number of subjects: 600
Study: 20176772

Group type: EXPERIMENTAL
Intervention: Group programme combining physical activity, education, self-management principles and a 'healthy options' morning tea, once-a-week for seven weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (before crossover)
Number of subjects: 42
Study: 18390975

Group type: EXPERIMENTAL
Intervention: 12-week high-intensity aerobic exercise programme
Number of subjects: 64

Group type: COMPARATOR
Intervention: Dexamethasone suppression test negative group (control)
Number of subjects: 64
Study: 17998631

Group type: EXPERIMENTAL
Intervention: RT+AK-2123
Number of subjects: 333

Group type: COMPARATOR
Intervention: RT
Number of subjects: 333
Study: 12088330

Group type: EXPERIMENTAL
Intervention: Negative priming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Different suggestibility measurement procedure
Number of subjects: 0
Study: 10363889

Group type: EXPERIMENTAL
Intervention: Primary Closure (PC)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene Patch Closure (PTFE)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Vein Patch Closure (VPC)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 399

Group type: COMPARATOR
Intervention: Comparison of Patching vs. Primary Closure
Number of subjects: 399

Group type: COMPARATOR
Intervention: Stenoses of 50%-80%
Number of subjects: 399

Group type: COMPARATOR
Intervention: Recurrent stenoses >= 80%
Number of subjects: 399
Study: 7573816

Group type: EXPERIMENTAL
Intervention: IgE detection in stools of food-sensitization patients
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: IgE detection in stools of carriers of intestinal parasites
Number of subjects: 434

Group type: COMPARATOR
Intervention: IgE detection in stools of healthy subjects
Number of subjects: 434

Group type: COMPARATOR
Intervention: Alpha-1-antitrypsin determination
Number of subjects: 434
Study: 2119901

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 30
Study: 508508

Group type: EXPERIMENTAL
Intervention: Single oral dose of metronidazole (500 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single intravenous dose of metronidazole (500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single dose of metronidazole (500 mg)
Number of subjects: 0
Study: 30801359

Group type: EXPERIMENTAL
Intervention: Bilateral ultrasound-guided erector spinae plane block using 20 mL of bupivacaine 0.25% on each side
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bilateral sham erector spinae plane block using 1 mL of normal saline
Number of subjects: 60
Study: 29728074

Group type: EXPERIMENTAL
Intervention: Varenicline plus 18 mg/mL nicotine e‐cigarette
Number of subjects: 338

Group type: COMPARATOR
Intervention: Varenicline alone
Number of subjects: 338
Study: 27184992

Group type: EXPERIMENTAL
Intervention: Intervention questionnaire including questions about QOL goals and concerns
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control questionnaire asking about symptoms
Number of subjects: 64
Study: 24635171

Group type: EXPERIMENTAL
Intervention: Bovine amniotic membrane (BAM)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Hydrocolloid dressing
Number of subjects: 49
Study: 22323297

Group type: EXPERIMENTAL
Intervention: Lower-body immersion in warm water at 42°C for 40 min (HOT)
Number of subjects: 7
Study: 20187757

Group type: EXPERIMENTAL
Intervention: Client-centred self-care intervention (CCSCI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ordinary training (Control group)
Number of subjects: 40
Study: 18005311

Group type: EXPERIMENTAL
Intervention: Drip irrigation kits
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Watering cans with caps from a height <0.5 m
Number of subjects: 396

Group type: COMPARATOR
Intervention: Watering cans without caps from a height >1 m
Number of subjects: 396
Study: 16184030

Group type: EXPERIMENTAL
Intervention: DAPD 25, 100, 200, 300 or 500 mg twice daily or 600 mg once daily monotherapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: DAPD 500 mg twice daily
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: DAPD 300 or 500 mg twice daily added to existing ART
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (ART‐experienced patients receiving existing ART)
Number of subjects: 90
Study: 12577355

Group type: EXPERIMENTAL
Intervention: Zhuhuang Frost (ZHF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Mayinglong Musk hemorrhoidal paste (MMHP)
Number of subjects: 50
Study: 9531251

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg/d + Ticlopidine 2X250 mg/d (Group A)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Ticlopidine 2X250 mg/d (Group B)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Aspirin 300 mg/d (Group C)
Number of subjects: 61
Study: 7980260

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg bd for a minimum of 5 pre-operative days, then intravenously for 2 postoperative days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no cimetidine treatment)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 2481774

Group type: EXPERIMENTAL
Intervention: Felodipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29076963

Group type: EXPERIMENTAL
Intervention: TR1 (3 × 10, 0-second rest)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CL10 (3 × 10, 10-second rest)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CL15 (3 × 10, 15-second rest)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TR2 (6 × 5, 0-second rest)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CL5 (3 × 10, 5-second rest)
Number of subjects: 10
Study: 31754119

Group type: EXPERIMENTAL
Intervention: Transmitted drug resistance (TDR)
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: NRTIs resistance
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: NNRTIs resistance
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: PIs resistance
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Triple-class resistance
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: InSTIs resistance
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Transmission clusters
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: TDR cluster
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Pre-treatment HIV resistance testing
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Surveillance of TDR to InSTI
Number of subjects: 403
Study: 28637418

Group type: EXPERIMENTAL
Intervention: Crocus sativus 100 mg/day for 12 weeks
Number of subjects: 44
Study: 25561192

Group type: EXPERIMENTAL
Intervention: Clamshell incision (CI)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Left anterolateral thoracotomy (LAT)
Number of subjects: 16
Study: 23733467

Group type: EXPERIMENTAL
Intervention: Metronidazole (500 mg thrice daily)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 21791363

Group type: EXPERIMENTAL
Intervention: Left Ventricular Cardiac Resynchronization Therapy (LV CRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biventricular Cardiac Resynchronization Therapy (Biventricular CRT)
Number of subjects: 0
Study: 19537855

Group type: EXPERIMENTAL
Intervention: Brackets bonded within 24 hours after bleaching
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Brackets bonded 2-3 weeks after bleaching
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Bleached teeth
Number of subjects: 38

Group type: COMPARATOR
Intervention: Unbleached teeth
Number of subjects: 38
Study: 16946127

Group type: EXPERIMENTAL
Intervention: Inhaled iloprost (5 mug) added to bosentan
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo added to bosentan
Number of subjects: 67
Study: 15464489

Group type: EXPERIMENTAL
Intervention: Prostacyclin (10 ng x kg(‐1) x min(‐1)) started 20 minutes before cross‐clamp removal and continued for 24 hours post-surgery
Number of subjects: 1190

Group type: COMPARATOR
Intervention: Control group (no prostacyclin treatment)
Number of subjects: 1190
Study: 11779437

Group type: EXPERIMENTAL
Intervention: Early intervention (Group I, n = 29)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Delayed intervention (Group II, n = 26)
Number of subjects: 55
Study: 9616522

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 1330
Study: 8092830

Group type: EXPERIMENTAL
Intervention: Imipenem monotherapy
Number of subjects: 280

Group type: COMPARATOR
Intervention: Imipenem plus netilmicin
Number of subjects: 280
Study: 3382463

Group type: EXPERIMENTAL
Intervention: Minocycline (7 X 100 mg for 3 days)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Minocycline (7 X 100 mg for 3 days) + Vitamin B6 (7 X 40 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo or initial non-drug investigation
Number of subjects: 40
Study: 30170260

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) - 385.6 mg EPA and 81.2 mg DHA/capsule, n=33
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) - 417.8 mg DHA and 50.8 mg EPA/capsule, n=33
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo (high oleic acid sunflower oil), n=33
Number of subjects: 99
Study: 29132734

Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg/day) and Vitamin D3 (50,000 IU every two weeks) for 8 weeks
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Vitamin E and D3 supplementation
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Vitamin D level
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Follicular fluid or serum MDA and TAC
Number of subjects: 105